Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.
Shunta AkutsuYasuaki MinoTakafumi NaitoKohei HoshikawaMasao SaotomeYuichiro MaekawaJunichi KawakamiPublished in: European journal of clinical pharmacology (2022)
This study clarified the racemic impact of CYP3A5 genotypes on tolvaptan metabolism. Amiodarone may stereoselectively interact with R-forms rather than S-forms of tolvaptan.